Understanding how leukemia stem cells evade elimination is one of the central puzzles in blood cancer biology — and a key reason why acute myeloid leukemia (AML) relapse rates remain stubbornly high even after apparent remission. A mechanistic answer to part of that puzzle now emerges from a study published in PNAS, with implications for how oncoproteins reach far beyond their primary transcriptional targets to rewire cellular metabolism.
The fusion oncoprotein AML1-ETO — produced by the chromosomal translocation t(8;21) and present in roughly 10–15% of AML cases — appears to exploit a distal enhancer element to amplify expression of NAT10, an enzyme that catalyzes ac4C RNA acetylation, a posttranscriptional modification that stabilizes specific messenger RNAs and enhances their translational efficiency. By upregulating NAT10, AML1-ETO selectively boosts translation of transcripts governing glutathione biosynthesis, effectively fortifying leukemia stem cells (LSCs) against oxidative stress. Glutathione, the cell's primary antioxidant buffer, is disproportionately relied upon by cancer stem cells that must manage elevated reactive oxygen species while maintaining self-renewal capacity.
This finding matters because it reveals a layered regulatory circuit — transcription factor → chromatin remodeling → RNA modification → metabolic reprogramming — that keeps LSCs viable and resistant to therapy. Most existing AML-targeted strategies focus on blocking kinases or differentiation pathways; the RNA acetylation axis has received far less pharmaceutical attention. NAT10 inhibitors, such as remodelin, have shown preclinical activity in other contexts, but their utility in AML had not been mechanistically grounded until this work. The study is a compelling mechanistic investigation, though its translational weight rests largely on cell-line and mouse model data, and clinical validation remains a necessary next step. Still, identifying a druggable epigenetic-to-epitranscriptomic link in LSC maintenance represents a meaningful conceptual advance in the field.